通过三重组合疗法克服IGF1R介导的对瘤性HSV1和放射治疗的抵抗
Research square
|January 9, 2026
概括
结合瘤性简单疹病毒-1 (oHSV) 治疗与IGF1R阻断和放射治疗,可以协同增强抗瘤效应. 这种三重组合克服了耐药性,并在乳腺癌和质母细胞瘤模型中改善了生存率.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 免疫治疗是一种免疫疗法.
背景情况:
- 瘤性简单疹病毒-1 (oHSV) 疗法对固体瘤有前途,但由于瘤微环境适应而面临阻力.
- 放射治疗 (RTx) 和oHSV可以激活IGF1R和YAP1等促生存途径,从而导致治疗耐药性.
研究的目的:
- 研究oHSV诱导的IGF1R/YAP1信号在瘤细胞存活和增殖中的作用.
- 评估将IGF1R封锁与oHSV和RTx结合以提高抗瘤功效的治疗潜力.
主要方法:
- 使用乳腺癌 (BC) 和质母细胞瘤 (GBM) 细胞系和异种移植模型进行体外和体内研究.
- 在oHSV,RTx和IGF1R抑制剂治疗后评估IGF1R和YAP1信号通路.
- 在组合疗法模型中评估细胞毒性,瘤生长抑制和生存率.
主要成果:
- oHSV激活IGF1R信号,促进瘤的扩散.
- 将IGF1R抑制剂与oHSV结合使用显示出适度的细胞毒性增加.
- 与oHSV和RTx同时治疗强烈激活IGF1R和YAP1,表明耐药性.
- 对oHSV,RTx和IGF1R阻断的三重组合显示出协同作用的抗瘤作用,废除了YAP1并改善了生存率.
结论:
- IGF1R/YAP1轴是对oHSV和RTx联合治疗耐药性的关键调解器.
- 三重组合疗法 (oHSV,RTx,IGF1R阻断) 提供了一种突破耐药性的协同策略.
- 这种方法需要对治疗BC和GBM患者进行临床评估.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


